Table 6.
Comparison of Gleason scores and core involvement rates with patients’ free and bioavailable testosterone levels divided by thresholds in PCa diagnosed group
| TT<350 | TT≥350 | p | FT≤5.5 | FT>5.5 | p | BT≤135 | BT>135 | p | |
|---|---|---|---|---|---|---|---|---|---|
| Gleason score <7 n (%) | 61 (76.5) | 56 (72.8) | 0.91 | 49 (69) | 76 (85.4) | 0.02 | 48 (62.4) | 69 (83.1) | 0.004 |
| Gleason score ≥7 n (%) | 22 (23.5) | 21 (27.2) | 22 (31) | 13 (14.6) | 29 (37.6) | 14 (16.9) | |||
|
| |||||||||
| Core involvement <50% n (%) | 73 (85.9) | 59 (78.7) | 0.29 | 51 (72.9) | 79 (87.8) | 0.02 | 55 (72.4) | 74 (88.1) | 0.016 |
| Core involvement 50% n (%) | 12 (14.1) | 16 (21.3) | 19 (27.1) | 11 (12.2) | 21 (27.6) | 10 (11.9) | |||
TT: total testosterone; FT: free testosterone; BT: bioavailable testosterone